TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03419819

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PKU Sphere
Description: PKU Sphere is a glycomacropeptide based alternative to amino-acid based products for the dietary management of phenylketonuria.
Study: NCT04476784

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A contact lenses
Description: Investigational silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A contact lenses
Description: Investigational silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lenses
Description: Commercially available silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lenses
Description: Commercially available silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based cleaning and disinfecting solution

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based cleaning and disinfecting solution
Study: NCT01006733

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic
Description: The pharmacogenetic arm estimates therapeutic warfarin dose using cytochrome P 450 2C9 (CYP2C9), vitamin K epoxide reductase complex subunit 1 (VKORC1), and cytochrome P 450 4F2 (CYP4F2) genotype and clinical information. The clinical arm estimates warfarin dose from clinical information alone.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic
Description: The pharmacogenetic arm estimates therapeutic warfarin dose using cytochrome P 450 2C9 (CYP2C9), vitamin K epoxide reductase complex subunit 1 (VKORC1), and cytochrome P 450 4F2 (CYP4F2) genotype and clinical information. The clinical arm estimates warfarin dose from clinical information alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Target INR 1.8
Description: We will randomize patients to a target International Normalized Ratio (INR) of 2.5 or 1.8.
Study: NCT01006733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Target INR 1.8
Description: We will randomize patients to a target International Normalized Ratio (INR) of 2.5 or 1.8.
Study: NCT02134184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® 2012-2013 Formula NDC No 498281-012-50
Description: This vaccine is given intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® 2012-2013 Formula NDC No 498281-012-50
Description: This vaccine is given intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® 2012-2013 Formula NDC No 498281-012-50
Description: This vaccine is given intramuscularly
Study: NCT00841815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine Besylate
Description: 10 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norvasc®
Description: 10 mg Tablet
Study: NCT02158481

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Placebo intervention
Study: NCT02652754

Intervention type: DRUG
Group type: OTHER
Intervention: Granexin® gel
Description: Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
Study: NCT00437983

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PS-Omega3
Description: Phosphatidylserine-Omega3 capsules 3x100mg/day 15 wk. Next, follow up phase, open label,1x100mg/day, 15 wk

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cellulose tainted with fishy odor capsules 3x100mg/day 15 wk
Study: NCT00822042

Intervention type: OTHER
Intervention: Samples and procedures
Description: * Scanner, histomorphometry : at the inclusion and M3 visits~* whole blood samples, cytoponction : at the inclusion and M3 visits
Study: NCT03676283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based psycho-educational support for family caregivers
Description: A website including potentially modifiable topics shown to be associated with preparedness. The topics cover areas such as knowledge about medical issues including symptoms and symptom relief, communication within the couple, how to spend the time before death, being partner or caregiver, planning of the moment of death and considerations of the partner's future, including psychological issues, logistical issues, economy, and the care for children.
Study: NCT04480008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilient Living Program
Description: Participants will be given the journal Resilient Living with Dr. Sood: Building Strength for Difficult Days to use throughout the study. The initial session with one of the investigators will be an introduction and a review of Module 1: Gratitude, and will last 30-60min. Three follow-up sessions will occur approximately every two weeks and the participants should view the videos before those virtual meetings (Session 2 will review Module II: Mindful Presence; Session 3 will review Module III: Kindness; Session 4 will review Module IV: Resilient Mindset). The videos will take approximately 30 minutes each to review and virtual sessions will each take 30-60 minutes.
Study: NCT04249531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin Inhalation Dry Powder
Description: Patient will inhale the weeks after iv amikacin, dry powder amikacin per inhalation once 400 mg, next week once 700 mg and the last week 1000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin Injectable Product
Description: patient wil receive one dose of 400 mg amikacine intravenously in week 1
Study: NCT02404220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNS Prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNS Prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNS Prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNS Prophylaxis
Study: NCT01780571

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP 5 cm H2O + PSV 5 cm H2O
Description: Patients in the intervention group received Continuous Positive Airway Pressure (5 cm H2O) and Pressure Supported Ventilation (5 cm H2O)
Study: NCT03719209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HealthVoyager
Description: HealthVoyager is a virtual reality application that allows providers to create customized representations for patients and share the results of endoscopic procedures via an interactive platform. The app can show both normal and abnormal endoscopic findings and anatomy. Families will also receive a web link so that they may access the procedure results via the app at home on their smartphone or tablet.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Practice
Description: Patients and families will receive handouts with printed images of their endoscopic findings, as per standard practice at Boston Children's Hospital.
Study: NCT01070251

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Participatory parent-focused intervention
Description: Parent workshops and internet-based support to establish healthy physical activity routines, added to existing state-sponsored PA program
Study: NCT00603980

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 1 mg
Description: Oral alprazolam 1 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 1 mg
Description: Oral alprazolam 1 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 1 mg
Description: Oral alprazolam 1 mg + Inhaled placebo
Study: NCT01070251

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: State-sponsored PA program
Description: Preschool children receive twice a week 60 minutes of physical activity lessons over 6 months by an external gym trainer

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: State-sponsored PA program
Description: Preschool children receive twice a week 60 minutes of physical activity lessons over 6 months by an external gym trainer
Study: NCT01413594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HABIT
Description: 90 hours of bimanual training over 3 weeks in a day camp environment
Study: NCT04463524

Intervention type: DEVICE
Intervention: Personal ECG digital sensor
Description: Patients in test group will receive personal ECG sensor and in control gropu will not.

Intervention type: DEVICE
Intervention: Personal ECG digital sensor
Description: Patients in test group will receive personal ECG sensor and in control gropu will not.
Study: NCT04083196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
Description: Injection vaccine produced by ChinaVaccineSerum ,containing HPV antigen protein, 270μg/1ml/bottle
Study: NCT01137903

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conservative surgery
Description: Osteotomy, phalangectomy, exostectomy, metatarsal head resection, articular resection, partial calcanectomy

Intervention type: DRUG
Group type: OTHER
Intervention: Ciprofloxacin
Description: 500 mg/ 12 hours during 90 days

Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: 875/125 mg/12 hours during 90 days

Intervention type: DRUG
Group type: OTHER
Intervention: Sulfamethoxazole trimethoprim
Description: Trimethoprim 160 mg / Sulfamethoxazole 800 mg 1/12 horas.
Study: NCT00603980

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 1 mg
Description: Oral alprazolam 1 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg
Description: Oral alprazolam 2 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg
Description: Oral alprazolam 2 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg
Description: Oral alprazolam 2 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg
Description: Oral alprazolam 2 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg
Description: Oral alprazolam 2 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg
Description: Oral alprazolam 2 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg
Description: Oral alprazolam 2 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg
Description: Oral alprazolam 2 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg
Description: Oral alprazolam 2 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg
Description: Oral alprazolam 2 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg
Description: Oral alprazolam 2 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg
Description: Oral alprazolam 2 mg + Inhaled placebo
Study: NCT02363439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly
Description: IMO-8400 at 0.6 mg/kg/wk or 1.2 mg/kg twice weekly as defined per Protocol 8400-401
Study: NCT00792584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etravirine
Description: Patient receives etravirine/ placebo or efavirenz / placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: patient receives efavirenz / placebo or etravirine / placebo
Study: NCT03791294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIAB: microcrystalline titanium dioxide with covalently linked monovalent silver ions
Description: TIAGIN vaginal capsule, composition: TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract
Study: NCT04122781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel K-wire fixation devices
Description: The patients received surgery using novel K-wire fixation devices

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novel K-wire fixation devices
Description: The patients received surgery using novel K-wire fixation devices
Study: NCT00688298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefyx PPS™ System
Description: A mesh implant intended for use as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advantage ™ System
Description: The Advantage Mesh implant is intended as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
Study: NCT03965624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ninlaro
Description: Oral ixazomib will be given on days 1, 8, 15 of a 28-day cycle, the investigator will start with first test dose levels of ixazomib of 3 mg and process with dose escalation, in case of non-response and no severe adverse events at cycle 1 (see above) or de-escalation in case of response and severe adverse events.
Study: NCT01719562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: Patients undergo MRI scans for left ventricular function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: Patients undergo MRI scans for left ventricular function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: Patients undergo MRI scans for left ventricular function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Tailored aerobic exercise program onsite and at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Tailored aerobic exercise program onsite and at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Living
Description: Healthy living presentations at a centralized meeting place and over the phone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Living
Description: Healthy living presentations at a centralized meeting place and over the phone.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Testing (CPET)
Description: Performed on the treadmill using the Bruce or Modified Bruce protocol based on current fitness level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Testing (CPET)
Description: Performed on the treadmill using the Bruce or Modified Bruce protocol based on current fitness level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: A self-administered 13-item scale to assess fatigue in participants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: A self-administered 13-item scale to assess fatigue in participants
Study: NCT00263887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha1-Proteinase Inhibitor (Human)
Description: Weekly infusion of 60 mg/kg body weight for 2 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin (Human) 20%, United States Pharmacopeia (USP)
Description: Weekly infusion for 2 years. Albumin (Human) 20% will be diluted with 5% glucose to a final concentration of 2.0%.
Study: NCT01503333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Receiving individual counseling with the school nurse, tailored feedback from computer program, and after-school physical activity club.
Study: NCT00603980

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg
Description: Oral alprazolam 2 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg
Description: Oral alprazolam 2 mg + Inhaled placebo
Study: NCT04635332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food literacy and physical activity promotion interactive group sessions + Developed health promotion intervention materials (booklet)
Description: Information, skills training, goal setting and feedback interactive group sessions to improve food literacy aimed at increasing consumption of fruits and vegetables~Information, skills training, goal setting and feedback interactive group sessions to increase engagement in moderate physical activity~Information and skills training to increase ability to evaluate nutrition information~In general, focus will be on increasing knowledge, skills and self-efficacy to develop a lifelong healthy and gastronomic relationship with food and physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developed health promotion intervention materials (booklet).
Description: In the control arm, participants will only be given the developed intervention materials (designed in form of the usual awareness programs). No group sessions will be conducted
Study: NCT00504478

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids
Description: omega-3 supplement will be given in addition to high complex carbohydrate diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high complex carbohydrate diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high complex carbohydrate diet
Study: NCT02394639

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: video-EEG monitoring

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video-EEG monitoring
Study: NCT03081728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interscalene Block with Ropivacaine Hcl 0.2% Inj Vil 10Ml
Description: bolus 10ml of 0.5% ropivacaine followed by infusion @ 2ml/hr of 0.2% ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV diclofenac and IV paracetamol
Description: iv diclofenac 75 mg TDS iv paracetamol 1gm TDS
Study: NCT03270592

Intervention type: OTHER
Group type: OTHER
Intervention: Service dog
Description: Use of a individualized certified service dog
Study: NCT04099641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Bavituximab IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection
Description: Pembrolizumab IV Infusion
Study: NCT06616376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-Embolism Stocking
Description: To prevent patients undergoing TKA surgery from being affected by one another, the patients were hospitalized in separate rooms, and the orthopedic clinic team was made aware of the situation. The patients in the control group were told not to remove their socks until the sutures were removed after the operation, whereas the patients in the experimental group were told to remove their socks on the 10th day after the operation, so the patients had no idea which group they were in.
Study: NCT06677853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol Maleate Gel+Placebo
Description: Subjects were applied with the 0.5% timolol maleate gel at the affected area twice a day, and with the placebo once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol Maleate Gel
Description: Subjects were applied with the 0.5% timolol maleate gel at the affected area 3 times a day for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were applied with placebo at the affected area 3 times a day for 24 weeks.
Study: NCT03823287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
Study: NCT02191566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 (452500ACH)
Description: S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXALIPLATIN (205803BIJ)
Description: Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months
Study: NCT04721496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Power and Speed
Description: Analysis of the power and speed of execution in 6 conditions of increasing instability Situation 1 is stable and basic execution. Condition 6 is the most unstable.~The participants performed 2 series of 3 repetitions in each of the situations. All the exercises were executed on the same day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Power and Speed
Description: Analysis of the power and speed of execution in 6 conditions of increasing instability Situation 1 is stable and basic execution. Condition 6 is the most unstable.~The participants performed 2 series of 3 repetitions in each of the situations. All the exercises were executed on the same day.